Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Supportive Care in Cancer

• Publication date

  1998-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s005200050008PMID 10975689
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumor bone diseases and osteoporosis in cancer patients : pathophysiology, diagnosis, and therapy

  2000cited by this paper
• Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.

  1998cited by this paper
• Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy.

  1997cited by this paper
• Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.

  1997cited by this paper
• Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy.

  1996cited by this paper
• Parathyroid hormone (PTH)-related protein(1-36) is equipotent to PTH(1-34) in humans.

  1996cited by this paper
• Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD).

  1995cited by this paper
• Humoral hypercalcemia of malignancy: Some enigmas on the clinical features

  1995cited by this paper
• 1211 Randomised double-blind comparison of pamidronate or clodronate for hypercalcaemia of malignancy: Effects on bone metabolism markers

  1995cited by this paper
• Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.

  1994cited by this paper
• Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone.

  1994cited by this paper
• Long-term follow up of breast cancer patients treated for hypercalcaemia with aminohydroxypropylidene bisphosphate (APD).

  1993cited by this paper
• Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.

  1993cited by this paper
• Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia.

  1993cited by this paper
• Circulating PTHrP concentrations in tumor‐induced hypercalcemia: Influence on the response to bisphosphonate and changes after therapy

  1993cited by this paper
• Treatment of resistant tumor-induced hypercalcemia with escalating doses of pamidronate (APD).

  1992cited by this paper
• Modified immunoradiometric assay of parathyroid hormone-related protein: clinical application in the differential diagnosis of hypercalcemia.

  1992cited by this paper
• Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia.

  1992cited by this paper
• Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer.

  1991cited by this paper
• Response to retreatment of malignant hypercalcemia with the bisphosphonate AHPrBP (APD): Respective role of kidney and bone

  1990influential reference
• Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients.

  1990cited by this paper
• Cancer-Associated Hypercalcemia: Morbidity and Mortality: Clinical Experience in 126 Treated Patients

  1990cited by this paper
• Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate.

  1988influential reference
• Comparison of the renal and skeletal actions of calcitonin in the treatment of severe hypercalcaemia of malignancy.

  1984cited by this paper

• Hypercalcaemia and hypocalcaemia: finding the balance

  2017cites this paper
• Interspecialty Differences in Physicians' Attitudes, Beliefs, and Reasons for Withdrawing or Withholding Hypercalcemia Treatment in Terminally Ill Patients

  2016cites this paper
• Malignancy associated hypercalcaemia-responsiveness to IV bisphosphonates and prognosis in a palliative population

  2016cites this paper
• Traitements inhibiteurs de la résorption osseuse en situation métastatique : bilan actuel et perspectives

  2015cites this paper
• The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease.

  2015cites this paper
• Denosumab: a new agent in the management of hypercalcemia of malignancy.

  2015cites this paper
• Treatment of Bisphosphonate-Resistant Hypercalcemia of Malignancy with Calcitonin

  2014cites this paper
• Physicians’ attitude toward recurrent hypercalcemia in terminally ill cancer patients

  2014influential citation
• Non-malignant causes of hypercalcemia in cancer patients: a frequent and neglected occurrence

  2013cites this paper
• Humoral hypercalcaemia of malignancy associated with squamous cell carcinoma of the anus

  2011cites this paper
• Drugs for hypercalcemia

  2008cites this paper
• Use of ibandronate in the prevention of skeletal events in metastatic breast cancer

  2008influential citation
• Receptor Activator of NF-κB Ligand Inhibition Suppresses Bone Resorption and Hypercalcemia but Does Not Affect Host Immune Responses to Influenza Infection1

  2007cites this paper
• Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection.

  2007cites this paper
• Tumor Induced Hypercalcemia in a Patient with Mediastinal Synovial Sarcoma

  2007cites this paper
• Hypercalcemia of malignancy remains a clinically relevant problem.

  2006cites this paper
• Hypercalcemia of malignancy remains a clinically relevant problem.

  2006cites this paper
• Effect of gallium nitrate on tamoxifen induced hypercalcemia in rats bearing mammary tumor.

  2006cites this paper
• The RANKL Inhibitor Osteoprotegerin (OPG) Causes Greater Suppression of Bone Resorption and Hypercalcemia Compared to Bisphosphonates in Two Models of Humoral Hypercalcemia of Malignancy

  2005cites this paper
• Increased Renal Calcium Reabsorption by Parathyroid Hormone–Related Protein Is a Causative Factor in the Development of Humoral Hypercalcemia of Malignancy Refractory to Osteoclastic Bone Resorption Inhibitors

  2005cites this paper
• Bisphosphonates in Oncology

  2005cites this paper
• The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.

  2005cites this paper
• Hypercalcemia of malignancy.

  2004cites this paper
• Treating cancer-related hypercalcemia with gallium nitrate.

  2004cites this paper
• Bisphosphonates in Oncology: Physiopathologic Bases and Clinical Activity

  2003cites this paper
• Zoledronic acid: an advance in tumour bone disease therapy and a new hope for osteoporosis

  2003cites this paper
• Emergencies of Calcium Homeostasis

  2003cites this paper
• Treatment of tumor-induced hypercalcemia: a solved problem?

  2003cites this paper
• Bisphosphonates for cancer patients: why, how, and when?

  2002cites this paper
• A cysteine protease inhibitor prevents suspension-induced declines in bone weight and strength in rats.

  2002cites this paper
• Treatment of malignant hypercalcaemia

  2002cites this paper
• Bisphosphonates in the Treatment of Metastatic Breast Cancer

  2001cites this paper